Key result
A computational workflow identified a common structural pattern in the flecainide binding site for Kv1.5 and Nav1.5 channels, consisting of a hydrophobic patch and a polar region.
Why the study?
Antiarrhythmic drugs for AF are limited by toxicity and modest efficacy, but theoretical models show combined Nav1.5 and Kv1.5 blockade yields synergistic antiarrhythmic effects without ventricular impact.
A common structural pattern for flecainide binding in Kv1.5 and Nav1.5 channels was identified, which may inform future multi-target directed ligand design for atrial fibrillation.
No immediate clinical implications for AF; leaves open multi-target ligand design informed by shared Kv1.5/Nav1.5 binding motifs.
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Its treatment includes antiarrhythmic drugs (AADs) to modulate the function of cardiac ion channels. However, AADs have been limited by proarrhythmic effects, non-cardiovascular toxicities as well as often modest antiarrhythmic efficacy. Theoretical models showed that combined blockade of Nav1.5 (and its current INa) and Kv1.5 (and its current, IKur) ion channels yield a synergistic anti-arrhythmic effect without effect on ventricles. We focused on Kv1.5 and Nav1.5 to search for structural similarities in their binding site (BS) for flecainide (a common blocker and widely prescribed AAD), as a first step for prospective rational multi-target directed ligand (MTDL) design strategies. We presented a computational workflow for flecainide BS comparison in a flecainide-Kv1.5 docking model and a solved structure of flecainide-Nav1.5 complex. The workflow includes docking, molecular dynamics, BS characterization and pattern matching. We identified a common structural pattern in flecainide BS for these channels. The latter belongs to the inner cavity and consist of a hydrophobic patch and a polar region, involving residues from S6 helix and P-loop. Since the rational MTDL design for AF is still incipient, our findings could advance multi-target atrial-selective strategies for AF treatment.
No takes yet. Share an insight, caveat, or question.
Mazola et al. (2022) studied Atrial fibrillation. Flecainide binding site comparison in Kv1.5 and Nav1.5 channels was evaluated on Structural similarities in the binding site for flecainide. A computational workflow identified a common structural pattern in the flecainide binding site for Kv1.5 and Nav1.5 channels, consisting of a hydrophobic patch and a polar region.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: